Vianda S Stel1, Ryan Awadhpersad1, Maria Pippias1, Manuel Ferrer-Alamar2, Patrik Finne3,4, Simon D Fraser5, James G Heaf6, Marc H Hemmelder7, Alberto Martínez-Castelao8, Johan de Meester9, Runolfur Palsson10,11, Friedrich C Prischl12, Mårten Segelmark13, Jamie P Traynor14, Rafael Santamaria15, Anna Varberg Reisaeter16, Ziad A Massy17,18, Kitty J Jager1. 1. ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. 2. Renal Registry Valencian Region, Generalitat Valencian, Spain. 3. Department of Nephrology, Helsinki University Hospital, Helsinki, Finland. 4. Finnish Registry for Kidney Diseases, Helsinki, Finland. 5. Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK. 6. Department of Medicine, Zealand University Hospital, Roskilde, Denmark. 7. Dutch Renal Registry Renine, Nefrovisie Foundation, Utrecht, the Netherlands. 8. Nephrology Department, Bellvitge's University Hospital, Hospitalet, Barcelona, Spain. 9. Department of Nephrology & Dialysis & Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium. 10. Division of Nephrology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland. 11. Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. 12. Department of Nephrology, Fourth Department of Internal Medicine, Klinikum Wels-Grieskirchen, Wels, Austria. 13. Department of Clinical Sciences Lund, Nephrology, Lund University, Skane University Hospital, Lund, Sweden. 14. Scottish Renal Registry, ISD Scotland, Glasgow, UK. 15. Nephrology Service, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain. 16. Norwegian Renal Registry, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway. 17. Division of Nephrology, Ambroise Pare University Hospital, APHP, University of Paris Ouest-Versailles-St-Quentin-en-Yvelines (UVSQ), Paris, France. 18. Institut National de la Sante et de la Recherche Medicale (INSERM) U1018, Team 5, CESP UVSQ, University Paris Saclay, Villejuif, France.
Abstract
AIM: To examine international time trends in the incidence of renal replacement therapy (RRT) for end-stage renal disease (ESRD) by primary renal disease (PRD). METHODS: Renal registries reporting on patients starting RRT per million population for ESRD by PRD from 2005 to 2014, were identified by internet search and literature review. The average annual percentage change (AAPC) with a 95% confidence interval (CI) of the time trends was computed using Joinpoint regression. RESULTS: There was a significant decrease in the incidence of RRT for ESRD due to diabetes mellitus (DM) in Europe (AAPC = -0.9; 95%CI -1.3; -0.5) and to hypertension/renal vascular disease (HT/RVD) in Australia (AAPC = -1.8; 95%CI -3.3; -0.3), Canada (AAPC = -2.9; 95%CI -4.4; -1.5) and Europe (AAPC = -1.1; 95%CI -2.1; -0.0). A decrease or stabilization was observed for glomerulonephritis in all regions and for autosomal dominant polycystic kidney disease (ADPKD) in all regions except for Malaysia and the Republic of Korea. An increase of 5.2-16.3% was observed for DM, HT/RVD and ADPKD in Malaysia and the Republic of Korea. CONCLUSION: Large international differences exist in the trends in incidence of RRT by primary renal disease. Mapping of these international trends is the first step in defining the causes and successful preventative measures of CKD.
AIM: To examine international time trends in the incidence of renal replacement therapy (RRT) for end-stage renal disease (ESRD) by primary renal disease (PRD). METHODS: Renal registries reporting on patients starting RRT per million population for ESRD by PRD from 2005 to 2014, were identified by internet search and literature review. The average annual percentage change (AAPC) with a 95% confidence interval (CI) of the time trends was computed using Joinpoint regression. RESULTS: There was a significant decrease in the incidence of RRT for ESRD due to diabetes mellitus (DM) in Europe (AAPC = -0.9; 95%CI -1.3; -0.5) and to hypertension/renal vascular disease (HT/RVD) in Australia (AAPC = -1.8; 95%CI -3.3; -0.3), Canada (AAPC = -2.9; 95%CI -4.4; -1.5) and Europe (AAPC = -1.1; 95%CI -2.1; -0.0). A decrease or stabilization was observed for glomerulonephritis in all regions and for autosomal dominant polycystic kidney disease (ADPKD) in all regions except for Malaysia and the Republic of Korea. An increase of 5.2-16.3% was observed for DM, HT/RVD and ADPKD in Malaysia and the Republic of Korea. CONCLUSION: Large international differences exist in the trends in incidence of RRT by primary renal disease. Mapping of these international trends is the first step in defining the causes and successful preventative measures of CKD.